BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

Rhea-AI Summary

BeyondSpring Inc. (NASDAQ: BYSI), a biopharmaceutical company focused on immuno-oncology therapies, will present a corporate overview at the Evercore ISI HealthCONx Conference on December 2, 2020. Dr. Lan Huang, Co-founder and CEO, will participate in a fireside chat at 9:15 am ET. Investors can access a live webcast and replay on BeyondSpring's website under the Investors section. The company's lead asset, plinabulin, is in a Phase 3 trial for non-small cell lung cancer and has received Breakthrough Therapy designation from the U.S. FDA for preventing chemotherapy-induced neutropenia.

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.

Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer of BeyondSpring will participate in a fireside chat session beginning at approximately 9:15 am ET.

A live webcast and replay of the webcast will be accessible on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentation" in the Investors section.

About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

Investor Contact:

Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-430-7577

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com
646-627-8387

FAQ

What will BeyondSpring discuss at the Evercore ISI HealthCONx Conference on December 2, 2020?

BeyondSpring will provide a corporate overview, highlighting its cancer therapies and clinical advancements.

Who is participating in the fireside chat at the HealthCONx Conference for BeyondSpring?

Dr. Lan Huang, Co-founder and CEO of BeyondSpring, will participate in the fireside chat.

Where can I watch the BeyondSpring conference presentation online?

The presentation will be available via live webcast on BeyondSpring's website under the Investors section.

What is the significance of plinabulin in BeyondSpring's pipeline?

Plinabulin is BeyondSpring's lead asset, currently in Phase 3 trials, and has received FDA Breakthrough Therapy designation.

What recent FDA designation has BeyondSpring received for plinabulin?

The U.S. FDA granted Breakthrough Therapy designation to plinabulin for preventing chemotherapy-induced neutropenia.